Investors sought to back process to protect blood

Created: 01 January 2022 | Written by Bob Sprague | Print | Hits: 1662

Walker

As a new year dawns, Jimmy Walker of Arlington continues his lengthy search for investors. While pursuing backers, a company to which he is connected has a patent pending for a process to protect blood.

Walker, who captained the Arlington Catholic football team decades ago, first told his story to YourArlington in 2018.

Years of research based on technology developed by the military in the 1960s for red cells, Walker's cryoblood pack process aims to eliminate shelf-life issues for all blood components.

A frozen container holding precious, lifesaving fluid seeks to overcome the downsides in standard packaging -- limited shelf life and doubts about uncontaminated blood.

The founder and chairman of C-Levelclone, a management company, who is a longtime Arlington resident, explained: "CryoMedic Technologies is the name we use for the patent technology and then license it to C-Levelclone LLC."

His company website says: "CryoMedic Technologies currently has a patent pending which utilizes a unique variable heat transfer technique that addresses both freezing at -196°C and thawing at ambient room temperature. A plastic bag material, the CryoBlood Pak® (FDA approved) is used to contain the blood during the process. There is also a patent pending fabrication technique for the container bag."

Walker provided an update: "We are introducing this technology to Italy, England, Africa and Dubai as well as others." His technology has been recognized by the Association for the Advancement of Blood & Biotherapies, formerly the American Academy of Blood Banking.

Learn more from a recent interview with Good News Planet.

In the 22-minute video are, clockwise from top left,Sunil M. Upadhye, an investment broker; Paul Sladkus, a veteran television executive; Walker and Dr. Ted Robinson, a surgeon who is part of C-Levelclone's medical advisory board.

Investors, please note: The basic research has been completed. Continuing clinical testing is in process.

Those interested should contact Walker at 617-799-4211 or This email address is being protected from spambots. You need JavaScript enabled to view it. for more information.